Abstract
Mast cells, the multi-functional secretory cells, are the pivotal effector cells in immune response, and contribute to the pathogenesis of many diverse diseases, like asthma and mastocytosis, by releasing numerous proinflammatory mediators. Pimecrolimus (SDZ ASM 981) is a derivative of the macrolactam ascomycin and is a member of the calcineurin inhibitor class of immunosuppressors. It inhibits the calcineurin-dependent activation of nuclear factor of activated T cells and the expression of a number of proinflammatory cytokines in turn. Pimecrolimus has high and selective anti-inflammatory activity within the skin, and with much lower potential to affect local and systemic immune responses. Therefore it has been widely used for treatment of various inflammatory skin diseases. It has a cellselective mode of action, and mast cells are its specific target cells. Pimecrolimus inhibits the release of both preformed and de novo synthesized mediators from activated mast cells and inhibits accumulation of mast cells by inducing apoptosis. Several experimental and clinical reports have demonstrated the successful application of pimecrolimus and other calcineurin inhibitors, such as tacrolimus and cyclosporine A, to treat mastocytosis, a spectrum of disorders characterized by mast cell hyperplasia, especially cutaneous mastocytosis. These new findings suggest that pimecrolimus and other calcineurin inhibitors may be a novel and effective therapeutic approach for mast cell-associated diseases such as asthma and mastocytosis.
Keywords: NFAT, macrophilin-12, immunosuppression, calcineurin, cell degranulation, apoptosis, mastocytosis, therapy, pimecrolimus, keratinocytes
Current Pharmaceutical Design
Title: Mast Cells as Targets of Pimecrolimus
Volume: 17 Issue: 34
Author(s): Zhongcai Ma and Zongjiu Jiao
Affiliation:
Keywords: NFAT, macrophilin-12, immunosuppression, calcineurin, cell degranulation, apoptosis, mastocytosis, therapy, pimecrolimus, keratinocytes
Abstract: Mast cells, the multi-functional secretory cells, are the pivotal effector cells in immune response, and contribute to the pathogenesis of many diverse diseases, like asthma and mastocytosis, by releasing numerous proinflammatory mediators. Pimecrolimus (SDZ ASM 981) is a derivative of the macrolactam ascomycin and is a member of the calcineurin inhibitor class of immunosuppressors. It inhibits the calcineurin-dependent activation of nuclear factor of activated T cells and the expression of a number of proinflammatory cytokines in turn. Pimecrolimus has high and selective anti-inflammatory activity within the skin, and with much lower potential to affect local and systemic immune responses. Therefore it has been widely used for treatment of various inflammatory skin diseases. It has a cellselective mode of action, and mast cells are its specific target cells. Pimecrolimus inhibits the release of both preformed and de novo synthesized mediators from activated mast cells and inhibits accumulation of mast cells by inducing apoptosis. Several experimental and clinical reports have demonstrated the successful application of pimecrolimus and other calcineurin inhibitors, such as tacrolimus and cyclosporine A, to treat mastocytosis, a spectrum of disorders characterized by mast cell hyperplasia, especially cutaneous mastocytosis. These new findings suggest that pimecrolimus and other calcineurin inhibitors may be a novel and effective therapeutic approach for mast cell-associated diseases such as asthma and mastocytosis.
Export Options
About this article
Cite this article as:
Ma Zhongcai and Jiao Zongjiu, Mast Cells as Targets of Pimecrolimus, Current Pharmaceutical Design 2011; 17 (34) . https://dx.doi.org/10.2174/138161211798357827
DOI https://dx.doi.org/10.2174/138161211798357827 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
Call for Papers in Thematic Issues
Blood-based biomarkers in large-scale screening for neurodegenerative diseases
Disease biomarkers are necessary tools that can be employ in several clinical context of use (COU), ranging from the (early) diagnosis, prognosis, prediction, to monitor of disease state and/or drug efficacy. Regarding neurodegenerative diseases, in particular Alzheimer’s disease (AD), a battery of well-validated biomarkers are available, such as cerebrospinal fluid ...read more
Current Pharmaceutical challenges in the treatment and diagnosis of neurological dysfunctions
Neurological dysfunctions (MND, ALS, MS, PD, AD, HD, ALS, Autism, OCD etc..) present significant challenges in both diagnosis and treatment, often necessitating innovative approaches and therapeutic interventions. This thematic issue aims to explore the current pharmaceutical landscape surrounding neurological disorders, shedding light on the challenges faced by researchers, clinicians, and ...read more
Diabetes mellitus: advances in diagnosis and treatment driving by precision medicine
Diabetes mellitus (DM) is a chronic degenerative metabolic disease with ever increasing prevalence worldwide which is now an epidemic disease affecting 500 million people worldwide. Insufficient insulin secretion from pancreatic β cells unable to maintain blood glucose homeostasis is the main feature of this disease. Multifactorial and complex nature of ...read more
Emerging and re-emerging diseases
Faced with a possible endemic situation of COVID-19, the world has experienced two important phenomena, the emergence of new infectious diseases and/or the resurgence of previously eradicated infectious diseases. Furthermore, the geographic distribution of such diseases has also undergone changes. This context, in turn, may have a strong relationship with ...read more
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Fractal Analysis of the Bone Marrow in Myelodysplastic Syndromes
Current Bioinformatics Recent Advances in Anti-inflammatory Potential of Pyridazinone Derivatives
Mini-Reviews in Medicinal Chemistry Neurotransmitters and Chemokines Regulate Tumor Cell Migration: Potential for a New Pharmacological Approach to Inhibit Invasion and Metastasis Development
Current Pharmaceutical Design Medial Vascular Calcification in Diabetes Mellitus and Chronic Kidney Disease: The Role of Inflammation
Cardiovascular & Hematological Disorders-Drug Targets Recent Progress in the Hesperetin Delivery Regimes: Significance of Pleiotropic Actions and Synergistic Anticancer Efficacy
Current Pharmaceutical Design Inhalable Submicronized Formulation of Budesonide by Antisolvent Nanoprecipitation: Process Optimization and in vitro Characterization
Micro and Nanosystems Consideration of Cytokines as Therapeutics Agents or Targets
Current Pharmaceutical Design Long-Term Benzodiazepine Use and Mortality: Are we Doing the Right Studies?
Current Drug Safety New Pharmacological Approaches to the Cholinergic System: An Overview on Muscarinic Receptor Ligands and Cholinesterase Inhibitors
Recent Patents on CNS Drug Discovery (Discontinued) The Therapeutic Potential of Toll-Like Receptor 7 Stimulation in Asthma
Inflammation & Allergy - Drug Targets (Discontinued) Pharmaceutical Care: Past, Present and Future
Current Pharmaceutical Design Cysteine Network (CYSTEINET) Dysregulation in Parkinson’s Disease: Role of N-acetylcysteine
Current Drug Metabolism Noteworthy Secondary Metabolites Naphthoquinones – their Occurrence, Pharmacological Properties and Analysis
Current Pharmaceutical Analysis Meet Our Editorial Board Member
Recent Patents on Inflammation & Allergy Drug Discovery Role of Nitric Oxide in the Modulation of Angiogenesis
Current Pharmaceutical Design Network Pharmacology of Ayurveda Formulation <i>Triphala</i> with Special Reference to Anti-Cancer Property
Combinatorial Chemistry & High Throughput Screening Recognition of Fungal Components by the Host Immune System
Current Protein & Peptide Science Current Trends and Future Strategies for the Global Impact of COVID-19 Pandemic
Coronaviruses Choosing Optimal Firstline Helicobacter pylori Therapy: a View from a Region with High Rates of Antibiotic Resistance
Current Pharmaceutical Design Structural Requirements of Heparin and Related Molecules to Exert a Multitude of Anti-Inflammatory Activities
Mini-Reviews in Medicinal Chemistry